Chelysheva, Ekaterina http://orcid.org/0000-0001-6423-1789
Apperley, Jane http://orcid.org/0000-0002-1710-1794
Turkina, Anna http://orcid.org/0000-0001-9947-2371
Yassin, Mohamed A.
Rea, Delphine
Nicolini, Franck E.
Barraco, Daniela
Kazakbaeva, Khamida
Saliev, Sukhrob
Abulafia, Adi Shacham
Al-Kindi, Salam http://orcid.org/0000-0001-6863-5748
Byrne, Jennifer
Robertson, Harry F.
Cerrano, Marco
Shmakov, Roman http://orcid.org/0000-0002-2206-1002
Polushkina, Evgenia
de Fabritiis, Paolo
Trawinska, Malgorzata Monika
Abruzzese, Elisabetta http://orcid.org/0000-0001-5228-6491
Funding for this research was provided by:
European Leukemia Net
Article History
Received: 13 November 2023
Revised: 7 February 2024
Accepted: 13 February 2024
First Online: 23 February 2024
Competing interests
: EC – speaker: Novartis, Pfizer, R-Pharm, consultancy: Ascentage Pharma, JA – speaker: Novartis, Bristol Myers Squibb, Incyte, honoraria: Novartis, Bristol Myers Squibb, Incyte, Research Funding: Pfizer, Incyte, AT – speaker: Novartis, Pfizer, R-Pharm, Amgen, consultancy/advisory board: Novartis, DR – Novartis, Incyte, Pfizer, Terns, FEN – consultancy: Sun Pharma Ltd, Novartis, speaker: Incyte Biosciences, board entity: Incyte Biosciences, Pfizer, Novartis, BMS-Celgene, research fundings: Incyte Biosciences, Novartis, ASA – consultancy: Novartis, JB – honoraria: Novartis, Incyte, Pfizer, MC – advisory board: Insight, Novartis, Italfarmaco, speaker: Servier, Abbvie, Janssen, PF – consultancy: Jazz, Jannsen, Abbvie, MMT – consultancy: Novartis, Takeda, EA – consultancy: BMS, Novaris, Incyte, Pfizer, advisory: BMS, Novaris, Incyte, Pfizer, SAK, MAY, DB, KhK, SS, HFR, RS and EP – nothing to disclose.